lilly oral glp-1 Aleniglipron: An Oral, Small Molecule GLP-1R Agonist Fast-Follower from Structure Therapeutics Lilly claims its oral GLP-1

In the phase 2 trial, nausea was reported by 16.2% of participants in the lowest dose groups but climbed to over 45% in higher dose groups without proper titration

That shift helped her and her doctors select a treatment plan that addressed her specific drivers of obesity

&& Info: Type: Flood Watch start_time_local: 2026-07-18T10:00:00-04:00 end_time_local: 2026-07-19T02:00:00-04:00 county_name: state: PA headline: Flood Watch from SAT 10:00 AM EDT until SUN 2:00 AM EDT county_fips: category: Met url: urgency: Unknown severity: Moderate certainty: Unknown geographicname: Carbon County state_name: Pennsylvania Bulletin: ...FLOOD WATCH REMAINS IN EFFECT FROM 10 AM EDT THIS MORNING THROUGH LATE TONIGHT

We estimate that roughly half of people affected by obesity in the US will be eligible to benefit from GLP-1s overall, around 50 million people

The role of GLP-1R in AD is reflected mainly in the following aspects: it can decrease A deposition and inhibit tau protein hyperphosphorylation, reduce neuroinflammation and oxidative stress (OS) ( 2.1 GLP-1R and A deposition A is a protein fragment produced by the cleavage of amyloid precursor protein (APP) by a series of enzymes and is one of the key factors in AD research (Figure 1)

The latest results come from ATTAIN-1, a large phase III study testing the effectiveness of orforglipron for people who are overweight or living with obesity